DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday. DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue came in at $994.2 million which beat the analyst consensus estimate of $990.71 million and is an increase over sales of $975 million from the same period last year.DexCom also announced Teri Lawver, executive vice president and chief commercial officer, will retire at the end of the year. Lawver w ...

DexCom, Inc. (DXCM) reported third-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which beat the Zacks Consensus Estimate of 43 cents by 4.7%. The company had reported earnings of 50 cents per share in the prior-year quarter. DXCM registered GAAP net income per share of 34 cents, up from the year-ago quarter's figure of 29 cents. Revenue Details of Dexcom Total revenues grew 2% (3% on an organic basis) to $994.2 billion year over year, beating the Zacks Consensus Estimate by 0.3%. The revenue g ...

My last article about DexCom, Inc. (NASDAQ: DXCM ) was published almost one and a half years ago and similar to my previous articles about Dexcom, I was bearish about the stock. And while there might be stocks, I am rather bearish about, IMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market ca ...

Financial Data and Key Metrics Changes - For Q3 2024, the company reported worldwide revenue of $994 million, a 2% increase compared to $975 million in Q3 2023, and a 3% organic growth [16] - US revenue was $702 million, down 2% from $714 million in Q3 2023, attributed to slower new customer starts and a decline in revenue per customer due to shifting channel dynamics [17] - International revenue grew 12% to $292 million, with organic growth at 16%, driven by stronger performance in core international markets [18] - Gross profit was $625.9 million, representing 63% of revenue, compared to 64.7% in Q3 2023 [19] - Operating income was $212 million, or 21.3% of revenue, down from $238.9 million, or 24.5% of revenue in Q3 2023 [20] - Net income for Q3 was $179.9 million, or $0.45 per share [20] Business Line Data and Key Metrics Changes - The company experienced record levels of new customer starts in Q3, with a prescriber base expansion of nearly 35,000 clinicians since the sales force expansion in April [9] - The DME channel saw some incremental share loss, but trends stabilized late in the quarter as the team aligned better with partners [18] - The launch of the G7 system in Australia and the DexCom ONE+ system in 19 countries contributed to international growth [11] Market Data and Key Metrics Changes - The US CGM market growth slowed to about 10% in Q3, down from over 20% in the first half of the year, raising concerns about market dynamics [26] - Japan returned to growth with the new sales organization gaining momentum, achieving the highest new customer start month since entering the market in 2019 [12] Company Strategy and Development Direction - The company is focused on expanding its sales force and improving commercial execution to drive growth [7] - The launch of Stelo is seen as a pivotal moment in diabetes care, providing access to a broader audience and enhancing the care model for patients [13] - The company aims to stabilize and grow its DME channel by fostering better relationships and increasing prescription referrals [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to higher growth and continued margin expansion, with expectations of improved sales force productivity [7] - The company is maintaining its 2024 revenue guidance of $4.00 billion to $4.05 billion, reflecting organic growth of 11% to 13% [21] - Management acknowledged the challenges faced in Q3 but emphasized the positive momentum heading into Q4 and 2025 [24] Other Important Information - The company submitted its DexCom G7 15-day CGM system to the FDA for review, which is a top priority for future growth [15] - The company closed the quarter with approximately $2.5 billion in cash and cash equivalents, providing financial flexibility [20] Q&A Session Summary Question: Insights on US market performance and DME share - Management acknowledged a rocky quarter but noted strong new patient additions and stabilization in DME share towards the end of Q3, indicating positive momentum moving forward [24] Question: Concerns about CGM market growth - Management remains bullish on the CGM market, believing it can grow faster than the current 10% rate, despite recent challenges [27] Question: Progress on new patient starts and long-range plan - Management confirmed that they are on track with their long-range plan, expecting continued improvement in new patient starts and sales force productivity [28] Question: Clarification on record new starts - Record new patient starts did not include Stelo, focusing solely on the G-Series/T-Series insulin product base [30] Question: DME channel stabilization efforts - Management detailed efforts to improve relationships with DME partners and emphasized the importance of increasing patient referrals through this channel [35] Question: Timing and financial impact of FDA approval for the 15-day G7 - Management refrained from speculating on approval timing but expressed optimism about the potential financial impact once launched [38] Question: Pricing strategy for Stelo with DME partners - Management indicated that pricing for Stelo through DME partners would account for their margins while maintaining low costs for the company [42] Question: Competition in the Type 1 pump integrated segment - Management highlighted the strong reputation of DexCom sensors and their ongoing collaboration with pump partners to maintain market share [44] Question: 2025 outlook and growth expectations - Management reiterated confidence in achieving the $4.6 billion revenue target for 2025, factoring in new product launches and market stabilization [46]

DexCom (DXCM) reported $994.2 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 2%. EPS of $0.45 for the same period compares to $0.50 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $991.55 million, representing a surprise of +0.27%. The company delivered an EPS surprise of +4.65%, with the consensus EPS estimate being $0.43. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...

DexCom (DXCM) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 4.65%. A quarter ago, it was expected that this medical device company would post earnings of $0.39 per share when it actually produced earnings of $0.43, delivering a surprise of 10.26%. Over the last four quarters, the co ...

| --- | --- | --- | --- | |-----------------|-------|----------|-------| | | | | | | | | | | | Dexcom | | | | | Dexcom earnings | | ny faces | | | Q3 2024 | | Nasdag | | | | | | | | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Table of Contents DEXCOM, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisd ...

Shares of Dexcom fell 9% in extended trading on Thursday after the company released third-quarter results that beat analysts' expectations but showed a decline in U.S. revenue year over year.Here's how the company did:Earnings per share: 45 cents adjusted vs. 43 cents expected by LSEGRevenue:  $994 million vs. $990 million expected by LSEGThe company's revenue increased 2% to $994.2 million from $975 million a year earlier. Dexcom's U.S. revenue declined 2% from $713.6 million the prior year. The company re ...

Revenue Performance - Revenue for Q3 2024 was $994.2 million, representing a 2% year-over-year growth on a reported basis and 3% on an organic basis[2]. - Total revenue for Q3 2024 was $994.2 million, a 2% increase from $975.0 million in Q3 2023[14]. - U.S. revenue decreased by 2%, while international revenue increased by 12% on a reported basis and 16% on an organic basis year-over-year[2]. - U.S. revenue decreased by 2% year-over-year to $701.9 million, while international revenue increased by 12% to $292.3 million[14]. - Sensor and other revenue grew by 9% year-over-year to $951.8 million, representing 96% of total revenue[15]. Income and Profitability - GAAP operating income was $152.0 million, or 15.3% of revenue, a decrease of 580 basis points compared to Q3 2023; Non-GAAP operating income was $212.0 million, or 21.3% of revenue, down 320 basis points year-over-year[2][5]. - GAAP net income for Q3 2024 was $134.6 million, or $0.34 per diluted share, compared to $120.7 million, or $0.29 per diluted share in Q3 2023[6]. - Net income for Q3 2024 increased to $134.6 million, compared to $120.7 million in Q3 2023[16]. - Basic net income per share rose to $0.34 from $0.31 year-over-year[16]. - Non-GAAP net income for Q3 2024 was $179.9 million, down from $202.8 million in Q3 2023[16]. - Adjusted EBITDA for Q3 2024 was $300.1 million, compared to $314.5 million in Q3 2023[16]. - GAAP net income for the three months ended September 30, 2024, was $134.6 million, up from $120.7 million for the same period in 2023, representing a 16.2% increase[17]. - Non-GAAP net income for the three months ended September 30, 2024, was $179.9 million, compared to $202.8 million in the prior year, reflecting a decrease of 11.3%[17]. - GAAP diluted net income per share for the three months ended September 30, 2024, was $0.34, an increase from $0.29 in the same quarter of 2023[17]. - Non-GAAP diluted net income per share for the three months ended September 30, 2024, was $0.45, down from $0.50 in the prior year, a decline of 10%[17]. - The company reported a GAAP net income of $424.5 million for the nine months ended September 30, 2024, compared to $285.2 million for the same period in 2023, marking a significant increase of 48.8%[17]. - Non-GAAP net income for the nine months ended September 30, 2024, was $482.4 million, up from $410.7 million in the previous year, indicating a growth of 17.5%[17]. Expenses and Financial Flexibility - Research and development expenses increased to $135.4 million, up from $131.4 million in Q3 2023[16]. - Total operating expenses for Q3 2024 were $441.8 million, compared to $417.8 million in Q3 2023[16]. - Cash and cash equivalents as of September 30, 2024, totaled $2.49 billion, providing significant financial flexibility for market expansion[7]. - The company incurred a nonrecurring $24.6 million non-cash inventory build charge and rent for vacated office space in San Diego, California, impacting the financial results for the three months ended September 30, 2024[17]. Product Development and Guidance - Launched Stelo, the first over-the-counter glucose biosensor in the U.S., targeting adults with prediabetes and type 2 diabetes not on insulin therapy[2]. - The company submitted the Dexcom G7 15-day CGM system to the FDA for review after the quarter ended[2]. - Dexcom is reiterating its 2024 revenue guidance of approximately $4.00 - 4.05 billion, indicating an expected organic growth of 11% to 13%[3]. Metrics and Adjustments - Non-GAAP gross profit margin for Q3 2024 was approximately 63.0%, down from 64.7% in Q3 2023[5]. - Adjustments related to taxes for the nine months ended September 30, 2024, were primarily due to the tax effect of non-GAAP adjustments and excess tax benefits from share-based compensation[18]. - The company emphasizes the importance of organic revenue as a metric for consistent comparison of revenue to prior periods and industry peers, excluding non-CGM revenue acquired or divested in the trailing twelve months[22].